Trimodal bladder-preserving treatment via maximum transurethral resection of bladder tumor followed by concurrent chemoradiation is safe and, when combined with early salvage RC for recurrence, offers long-term survival rates in selected patients comparable to RC. Adjuvant (Adj) cisplatin-based combination chemotherapy may be considered, particularly for pT3-4 and/or pN+ disease without prior NA chemotherapy. Neoadjuvant (NA) cisplatin-based combination chemotherapy improves overall survival and should be offered to eligible ≥ cT2N0 patients. While associated with substantial morbidity and mortality, this has been mitigated with improved technique, minimally invasive technology, and better perioperative care pathways (e.g., enhanced recovery after surgery). Radical cystectomy (RC) is the standard of care for MIBC patients considered to be surgical candidates. An international multi-disciplinary expert panel evaluated and graded the data according to guidelines from the Oxford Centre for Evidence-Based Medicine. provide a comprehensive overview and update of the Joint Société Internationale d'Urologie-International Consultation on Urological Diseases (SIU-ICUD) Consultation on Bladder Cancer for muscle-invasive presumably node-negative bladder cancer (MIBC).Ĭontemporary literature was analyzed for the latest evidence in treatment options, outcomes, including radical surgery, neoadjuvant and adjuvant treatment modalities, and bladder-sparing approaches. 16 Department of Urology, University of Tübingen, Tübingen, Germany. 15 PSMAR-IMIM Hospital del Mar Medical Research Institute, Barcelona, Spain. 14 Genitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.1 Department of Urology, Tan Tock Seng Hospital, Singapore, Singapore. 13 Department of Urology, University of Lille Nord de France, Lille, France.12 Genitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.11 Department of Urology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.10 Department of Radiation Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.9 Department of Urology, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.8 Department of Urology, University Hospital of Cologne, Cologne, Germany.7 Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.6 USC Institute of Urology, University of Southern California, Los Angeles, CA, USA.4 Department of Molecular Medicine and Surgery (MMK), Karolinska Institutet, Solna, Sweden.3 Department of Urology and Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA. 2 Department of Urology, University of Tübingen, Tübingen, Germany.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |